In this video interview, Dr Vitaly Margulis, from the University of Texas Southwestern Medical Center in Dallas, outlines the advantages of stereotactic body radiation therapy (SBRT) and talks about the forthcoming RADVAX clinical trial in the USA, which combines radiotherapy and immunotherapy.

Oncologists are often taught that renal cell carcinoma (RCC) is resistant to radiotherapy. However, treatments such as stereotactic body radiation therapy (SBRT) can be safe and effective in certain patients with RCC.

Watch the video interview on Urology Times here